At a press conference at EHA 2014, Dr Zafer Basler presented the results of a multicentre study that was conducted in Turkey to evaluate the efficacy and tolerability of generics for chronic myeloid leukaemia patients. It was found that there was no significant difference between the groups regarding response and resistance rates, and the rates of haematological and non-haematological adverse events.

Read the article for more.